Questions over the supply situation for Cuprenil in Russia

14 March 2023

Russia may face a shortage of rare disease drug Cuprenil (penicillamine), according to government procurement statistics data and the statistics of the commercial retail, reports The Pharma Letter’s local correspondent.

Cuprenil, from Israeli drugmaker Teva Pharmaceutical Industries (NYSE: TEVA), is intended for the treatment of the rare hereditary Wilson’s disease, a rare genetic disorder in which excess copper builds up in the body.

The risk of a shortage of Cuprenil in Russia first appeared in 2020, when Teva announced its plans to completely stop supplying eight of its drugs to the Russian market, including Cuprenil. A replacement for it existed only formally in 2019, when the Russian firm Nativa (now PharmMental Group) registered a generic penicillamine, although without registering its maximum price.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK